100 help plan
Nuotai Biotech: Net profit is expected to increase by 16% year-on-year in 202318% to 2393%】
Nuotai Biotech announced that it is expected to have a net profit of 1 in 2023500 million yuan-1600 million yuan, an increase of 16 percent year-on-year18% to 2393%。During the reporting period, thanks to the continuous increase in the volume of some preparations and peptide APIs in the company's independently selected products, the company's 2023 annual performance achieved a large year-on-year growth.
Winbond Health: It is planned to repurchase shares for 20 million yuan to 30 million yuan
Winbond Health announced that the company intends to repurchase the company's issued part of the ** through centralized bidding transactions, and use the aforementioned repurchased shares for equity incentive plans or employee stock ownership plans in the future. The total amount of repurchase funds shall not be less than 20 million yuan, not more than 30 million yuan, and the repurchase ** shall not be higher than 7$21 shares.
Heavy Pharmaceutical Holdings: The chairman intends to increase his shareholding in the company with no more than 1 million yuan
Heavy Pharmaceutical Holdings announced that the chairman intends to increase his holdings of the company's shares with no more than 1 million yuan, and the increase plan does not set a ** range.
Tongda shares: chairman resignation].
Tongda announced that the board of directors received a written resignation report from Mr. Zhang Zhenjiang today. Mr. Zhang Zhenjiang applied for resignation as the chairman of the board of directors, a director, the chairman of the strategy committee and a member of the nomination committee of the sixth session of the company due to work arrangements. After his resignation from the above positions, Mr. Zhang Zhenjiang no longer holds any position in the Company. As of the disclosure date of this announcement, Mr. Zhang Zhenjiang did not hold any shares of the Company.
Haichuang Pharmaceutical: Completed the enrollment of the first subject in the clinical trial of HP518 tablets in China
Haichuang Pharmaceutical announced that the clinical trial of HP518 tablets, an oral PROTAC drug, has completed the enrollment of the first subject in China.
Fosun Pharma: The drug of its holding subsidiary has obtained the Fast Track qualification of the US FDA
Fosun Pharma announced that its holding subsidiary, Shanghai Henlius Biotechnology Co., Ltd., recently received a fast track designation ( i.e. Express Entry Eligibility) Certification.